RxDoctor Payments Data

Sarfaraz Jasdanwala, MD

Addiction Medicine · Rolla, MONPI 1851646665

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 60.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $12,084 and has fallen 52.6% since, to $5,725 in 2025.

$25,722in general payments, 2019–2025

Across 47 payments — averaging $547.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$16K
  • Gilead$10K
  • Saol Therapeutics Inc.$260
  • Exact Sciences$15

What the payments were for

  • Consulting fees$6,09024%
  • Speaking & faculty fees$13,58053%
  • Travel & lodging$4,92619%
  • Food & beverage$1,1134%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alkermes, Inc.25$15,653
Gilead20$9,794
Saol Therapeutics Inc.1$260
Exact Sciences1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few addiction medicine providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$15,644
Medicare patients
23
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VivitrolNaltrexone Microspheres16$26,475
OzempicSemaglutide18$23,174
TrulicityDulaglutide23$17,543
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl224$11,915
Ondansetron Hcl97$7,879
Acamprosate Calcium28$3,705
Naltrexone Hcl63$2,951
SuboxoneBuprenorphine Hcl/Naloxone Hcl26$1,940
Bupropion XlBupropion Hcl74$1,093
Baclofen116$1,041
Hydroxyzine Pamoate125$958
Trazodone Hcl101$892
Olanzapine41$816
Quetiapine Fumarate69$742
Topiramate94$736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Vivitrol$15,653$26,47516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in Missourion file to place this against a meaningful peer group, so we don't.

Other addiction medicine in Rolla

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →